source
- GSK to spend up to $1.3 billion on Hutchmed's dual-target cancer therapyGSK announced a deal to acquire the majority rights to Hutchmed's experimental therapy HMPL-A830. The agreement includes an upfront payment of $110 million and potential milestone and royalty payme…
- Akeso's ivonescimab shows survival advantage over Keytruda in Chinese lung cancer trialA new data cut from a study comparing ivonescimab, a bispecific antibody from China-based Akeso, with Merck's Keytruda in patients with non-small cell lung cancer was released. The interim results…